Stenotrophomonas maltophilia: Difference between revisions
From IDWiki
Stenotrophomonas maltophilia
(Imported from text file) |
m (Text replacement - "[[Cellular shape::" to "[[Shape::") |
||
(14 intermediate revisions by the same user not shown) | |||
Line 1: | Line 1: | ||
==Background== |
|||
⚫ | |||
== |
===Microbiology=== |
||
* |
*Aerobic, non-fermentive, catalase [[Catalase::positive]], oxidase [[Oxidase::negative]], [[Stain::Gram-negative]] [[Shape::bacillus]] |
||
*Multiple mechanisms of resistance |
|||
**RND, MfsA, and Sme-related efflux pumps |
|||
**''Sul'' or ''dfrA'' genes (TMP-SMX resistance) |
|||
**β-lactamases |
|||
**Aminoglycoside-modifying enzymes |
|||
== |
==Clinical Manifestations== |
||
* |
*Nosocomial infections with high mortality and high antibiotic resistance |
||
== |
==Management== |
||
* |
*Limited antibiotic options |
||
*Therapy should be guided by antimicrobial susceptibility testing |
|||
** Levofloxacin (and other FQs) |
|||
*Antistenotrophomonal antibiotics: |
|||
** TMP-SMX (Septra) |
|||
**[[Is treated by::TMP-SMX]] 15 mg/kg split q8h (preferred agent, if susceptible) |
|||
** Doxycycline |
|||
**[[Is treated by::Fluoroquinolones]], including [[Is treated by::moxifloxacin]], [[Is treated by::levofloxacin]], and [[Is treated by::ciprofloxacin]] (though develops resistance quickly on monotherapy) |
|||
** Maybe also ticarcillin-clavulanate and ceftazidime |
|||
**[[Is treated by::Minocycline]], [[Is treated by::doxycycline]], and [[Is treated by::tigecycline]] |
|||
**[[Is treated by::Ticarcillin-clavulanate]] and [[Is treated by::ampicillin-sulbactam]] |
|||
**[[Is treated by::Ceftazidime]] and [[Is treated by::ceftazidime-avibactam]] |
|||
**[[Is treated by::Colistin]], though high rates of resistance |
|||
**Possibly [[Is treated by::ceftriaxone]] |
|||
⚫ | |||
[[Category:Gram-negative bacilli]] |
Latest revision as of 18:24, 13 October 2020
Background
Microbiology
- Aerobic, non-fermentive, catalase positive, oxidase negative, Gram-negative bacillus
- Multiple mechanisms of resistance
- RND, MfsA, and Sme-related efflux pumps
- Sul or dfrA genes (TMP-SMX resistance)
- β-lactamases
- Aminoglycoside-modifying enzymes
Clinical Manifestations
- Nosocomial infections with high mortality and high antibiotic resistance
Management
- Limited antibiotic options
- Therapy should be guided by antimicrobial susceptibility testing
- Antistenotrophomonal antibiotics:
- TMP-SMX 15 mg/kg split q8h (preferred agent, if susceptible)
- Fluoroquinolones, including moxifloxacin, levofloxacin, and ciprofloxacin (though develops resistance quickly on monotherapy)
- Minocycline, doxycycline, and tigecycline
- Ticarcillin-clavulanate and ampicillin-sulbactam
- Ceftazidime and ceftazidime-avibactam
- Colistin, though high rates of resistance
- Possibly ceftriaxone